MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients

Completed · Phase 1

Conditions studied: Fungal Infection

In brief

The primary purpose of this study is to identify the optimal dose of voriconazole, an anti-fungal drug often used in people undergoing stem cell transplant. An optimal dose level is one level that provides a good blood level (concentration) of voriconazole without too much toxicity.

Key facts

Study ID
NCT02227797
Run by
Masonic Cancer Center, University of Minnesota
People needed
66
Starts
2015-01-19
Expected to finish
2019-03-01
Last updated by the study team
2019-04-29

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.